The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ALIBABA GROUP HOLDING LIMITED | SPONSORED ADS | 01609W102 | 4,772 | 60,000 | SH | SOLE | 60,000 | 0 | 0 | ||
| ATYR PHARMA INC | COM | 002120103 | 777 | 279,425 | SH | SOLE | 279,425 | 0 | 0 | ||
| BIOCRYST PHARMACEUTICALS INC | COM | 09058V103 | 1,221 | 430,000 | SH | SOLE | 430,000 | 0 | 0 | ||
| BIOMARIN PHARMACEUTICAL INC | COM | 09061G101 | 7,019 | 90,215 | SH | SOLE | 90,215 | 0 | 0 | ||
| CELLDEX THERAPUETICS INC | COM | 15117B103 | 220 | 50,000 | SH | SOLE | 50,000 | 0 | 0 | ||
| HERON THERAPEUTICS INC | COM | 427746102 | 106,024 | 5,873,891 | SH | SOLE | 5,873,891 | 0 | 0 | ||
| HERON THERAPEUTICS INC | COM | 427746102 | 5,836 | 323,307 | SH | OTR | 1 | 0 | 323,307 | 0 | |
| IGNYTA INC | COM | 451731103 | 21,533 | 3,972,800 | SH | SOLE | 3,972,800 | 0 | 0 | ||
| LA JOLLA PHARMACEUTICAL CO | COM | 503459604 | 48,834 | 3,052,130 | SH | SOLE | 3,052,130 | 0 | 0 | ||
| LIPOCINE INC | COM | 53630X104 | 790 | 260,000 | SH | SOLE | 260,000 | 0 | 0 | ||
| MERRIMACK PHARMACEUTICALS INC | NOTE 4.5% 7/15/20 | 590328AA8 | 3,965 | 3,500,000 | PRN | SOLE | 3,500,000 | 0 | 0 | ||
| NEKTAR THERAPEUTICS | COM | 640268108 | 3,700 | 260,000 | SH | SOLE | 260,000 | 0 | 0 | ||
| OPKO HEALTH INC | DEBT 3.0% 2/1/33 | 68375NAB9 | 19,753 | 14,000,000 | PRN | SOLE | 14,000,000 | 0 | 0 | ||